S
Scott S. Tykodi
Researcher at Fred Hutchinson Cancer Research Center
Publications - 115
Citations - 11516
Scott S. Tykodi is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Nivolumab & Renal cell carcinoma. The author has an hindex of 25, co-authored 91 publications receiving 9209 citations. Previous affiliations of Scott S. Tykodi include Washington University in St. Louis & University of Washington.
Papers
More filters
Journal ArticleDOI
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer,Scott S. Tykodi,Scott S. Tykodi,Laura Q.M. Chow,Wen-Jen Hwu,Suzanne L. Topalian,Patrick Hwu,Charles G. Drake,Luis H. Camacho,John S. Kauh,Kunle Odunsi,Henry C. Pitot,Omid Hamid,Shailender Bhatia,Renato G. Martins,Keith D. Eaton,Shuming Chen,Theresa M. Salay,Suresh Alaparthy,Joseph F. Grosso,Alan J. Korman,Susan M. Parker,Shruti Agrawal,Stacie M. Goldberg,Drew M. Pardoll,Ashok Kumar Gupta,Jon M. Wigginton +26 more
TL;DR: Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Journal ArticleDOI
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert J. Motzer,Brian I. Rini,David F. McDermott,Osvaldo Arén Frontera,Hans J. Hammers,Michael A. Carducci,Pamela Salman,Bernard Escudier,Benoit Beuselinck,Asim Amin,Camillo Porta,Saby George,Victoria Neiman,Sergio Bracarda,Scott S. Tykodi,Philippe Barthélémy,Raya Leibowitz-Amit,Elizabeth R. Plimack,Sjoukje F. Oosting,Bruce G. Redman,Bohuslav Melichar,Thomas Powles,Paul Nathan,Stéphane Oudard,David Pook,Toni K. Choueiri,Frede Donskov,Marc-Oliver Grimm,Howard Gurney,Daniel Y.C. Heng,Christian Kollmannsberger,Michael R. Harrison,Yoshihiko Tomita,Ignacio Duran,Viktor Grünwald,M. Brent McHenry,Sabeen Mekan,Nizar M. Tannir,CheckMate Investigators +38 more
TL;DR: Results showed that nivolumab plus ipilimumab continued to be superior to sunitinib in terms of overall survival and characterisation of response, and safety after extended follow-up in intermediate-risk or poor-risk patients.
Journal Article
Treatment of metastatic melanoma: an overview.
TL;DR: The treatments for metastatic melanoma are reviewed including promising investigational approaches including high-dose interleukin-2 and immunotherapeutic approaches associated with durable responses in a small percentage of patients.
Journal ArticleDOI
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine
John Wrangle,Wei Wang,Alexander Koch,Hariharan Easwaran,Helai P. Mohammad,Frank P. Vendetti,Wim Vancriekinge,Timothy Demeyer,Zhengzong Du,Princy Parsana,Kristen Rodgers,Ray-Whay Chiu Yen,Cynthia A. Zahnow,Janis M. Taube,Julie R. Brahmer,Scott S. Tykodi,Keith Easton,Richard D. Carvajal,Peter A. Jones,Peter W. Laird,Daniel J. Weisenberger,Salina Tsai,Rosalyn A. Juergens,Suzanne L. Topalian,Charles M. Rudin,Malcolm V. Brock,Drew M. Pardoll,Stephen B. Baylin +27 more
TL;DR: It is hypothesize that epigenetic therapy combined with blockade of immune checkpoints – in particular the PD-1/PD-L1 pathway – may augment response of NSCLC by shifting the balance between immune activation and immune inhibition, particularly in a subset ofNSCLC with low expression of AZA-induced immune genes.
Journal ArticleDOI
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
Hiroki Torikai,Andreas Reik,Frank Soldner,Edus H. Warren,Carrie Yuen,Yuanyue Zhou,Denise L. Crossland,Denise L. Crossland,Helen Huls,Nicholas Littman,Ziying Zhang,Scott S. Tykodi,Partow Kebriaei,Dean A. Lee,Dean A. Lee,Jeffrey C. Miller,Edward J. Rebar,Michael C. Holmes,Rudolf Jaenisch,Richard E. Champlin,Philip D. Gregory,Laurence J.N. Cooper,Laurence J.N. Cooper +22 more
TL;DR: It is established that clinically appealing cell types derived from donors with disparate HLA expression can be genetically edited to evade an immune response and provide a foundation whereby cells from a single donor can be administered to multiple recipients.